Vascepa

"The U.S. Food and Drug Administration today approved Kynamro (mipomersen sodium) injection as an addition to lipid-lowering medications and diet to treat patients with a rare type of high cholesterol called homozygous familial hypercholesterolemi"...

Vascepa

SIDE EFFECTS

Clinical Trials Experience

Because clinical trials are conducted under widely
varying conditions, adverse reaction rates observed in the clinical trials of a
drug cannot be directly compared to rates in the clinical trials of another
drug and may not reflect the rates observed in practice.

Adverse reactions reported in at least 2% and at a
greater rate than placebo for patients treated with VASCEPA based on pooled
data across two clinical studies are listed in Table 1.

DRUG INTERACTIONS

Anticoagulants

Some published studies with omega-3 fatty acids have
demonstrated prolongation of bleeding time. The prolongation of bleeding time
reported in those studies has not exceeded normal limits and did not produce
clinically significant bleeding episodes. Patients receiving treatment with
VASCEPA and other drugs affecting coagulation (e.g., anti-platelet agents)
should be monitored periodically.